OS Therapies Incorporated (NYSEAMERICAN:OSTX) Sees Significant Growth in Short Interest

OS Therapies Incorporated (NYSEAMERICAN:OSTX) saw a significant increase in short interest in February. As of February 13th, there was short interest totaling 1,372,865 shares, an increase of 42.2% from the January 29th total of 965,726 shares. Approximately 4.3% of the shares of the stock are short sold. Based on an average daily volume of 662,229 shares, the days-to-cover ratio is presently 2.1 days. Based on an average daily volume of 662,229 shares, the days-to-cover ratio is presently 2.1 days. Approximately 4.3% of the shares of the stock are short sold.

OS Therapies Stock Up 2.8%

Shares of OS Therapies stock traded up $0.04 on Friday, hitting $1.47. 216,653 shares of the company’s stock traded hands, compared to its average volume of 461,383. The stock has a market cap of $51.76 million, a P/E ratio of -1.79 and a beta of -3.79. The firm’s 50-day moving average is $1.40 and its 200 day moving average is $1.77. OS Therapies has a 52-week low of $1.12 and a 52-week high of $2.57.

Institutional Investors Weigh In On OS Therapies

A number of hedge funds have recently made changes to their positions in OSTX. CM Management LLC grew its position in OS Therapies by 6.7% in the 3rd quarter. CM Management LLC now owns 400,000 shares of the company’s stock valued at $784,000 after buying an additional 25,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in OS Therapies by 31.1% during the fourth quarter. Geode Capital Management LLC now owns 246,038 shares of the company’s stock worth $344,000 after purchasing an additional 58,350 shares in the last quarter. Millennium Management LLC acquired a new stake in OS Therapies in the third quarter worth approximately $183,000. Two Sigma Investments LP bought a new position in OS Therapies during the third quarter valued at about $169,000. Finally, Virtu Financial LLC grew its stake in shares of OS Therapies by 252.0% in the 3rd quarter. Virtu Financial LLC now owns 75,801 shares of the company’s stock worth $149,000 after purchasing an additional 54,269 shares during the last quarter.

Analysts Set New Price Targets

OSTX has been the subject of a number of recent research reports. D. Boral Capital reiterated a “buy” rating and set a $20.00 price objective on shares of OS Therapies in a research report on Thursday, February 5th. Lake Street Capital reduced their price target on OS Therapies from $18.00 to $17.00 and set a “buy” rating on the stock in a research note on Tuesday, November 18th. Finally, Zacks Research raised OS Therapies from a “strong sell” rating to a “hold” rating in a research note on Tuesday, November 11th. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $18.50.

About OS Therapies

OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.